Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data
Oncology · 02.03.2026 · 104 (8) · 891-899
DOI: 10.1159/000550347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 02.03.2026. Verfasst von Alexandre Gravian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Aigüe en Cancérologie, Gustave Roussy, Villejuif, France, alexandre.gravian@gustaveroussy.fr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Weight Loss, Immune Checkpoint Inhibitors. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Introduction
In studies, weight loss is strongly associated with outcomes in metastatic non-squamous cell lung cancer (mNSCLC). This work examines weight variations in first-line treatment, exploring their mechanisms based on treatment type, age, sex, weight loss, and excess weight before treatment.
Methods
A retrospective analysis was conducted on patients undergoing first-line treatment. Weight was recorded at four points: before treatment (Wbe), day 1 of treatment (Wd1), 3 months into immune checkpoint inhibitors (ICIs) treatment or maintenance (W3mo), and at progression diagnosis (Wpro).
Results
Among patients (n = 198), 47% received chemotherapy (CT) with ICIs, 26% CT alone, and 27% ICIs alone. At Wd1, 32% were overweight/obese (body mass index kg/m2) (BMI ≥ 25). Weight loss ≥ 5% before treatment was observed in 37%. Mean (SD) weight variations between Wd1 and W3mo were −1.1% (4.6) (CT), −0.2% (7.1) (CT+ICIs), and +0.4% (7.7) (ICIs alone) (p = 0.52). Patients older than 70 compared to ≤70 lost more weight between Wd1 and Wpro (−4.7% vs. −0.4%) (p = 0.019). Patients with pre-treatment weight loss ≥ 5% compared to those without weight loss stabilized or gained weight during treatment (+2.1% vs. −1.5%) (p = 0.009). Patients with BMI ≥ 25 lost more weight during treatment than those with BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Médecine Aigüe en Cancérologie, Gustave Roussy, Villejuif, France, alexandre.gravian@gustaveroussy.fr.
- Bureau de Biostatistique et d'Epidémiologie, Gustave Roussy, et CESP U1018, Oncostat, Labellisé Ligue Contre le Cancer, Inserm, Villejuif, France.
- Service de Médecine Aigüe en Cancérologie, Gustave Roussy, Villejuif, France.
- Département Interdisciplinaire d'Organisation du Parcours Patient (DIOPP), Gustave Roussy, Villejuif, France.
Zitieren
APA
Gravian, A., Pagès, A., Tarabay, A., Delaye, V., Scottée, F., Merad, M., & Antoun, S. (2026). Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data. Oncology, 104(8), 891-899. https://doi.org/10.1159/000550347
Vancouver
Gravian A, Pagès A, Tarabay A, Delaye V, Scottée F, Merad M, et al. Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data. Oncology. 2026;104(8):891-899. doi:10.1159/000550347
BibTeX
@article{Gravian2026,
author = {Gravian, Alexandre and Pagès, Arnaud and Tarabay, Anthony and Delaye, Virginie and Scottée, Florian and Merad, Mansouria and Antoun, Sami},
title = {Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data},
journal = {Oncology},
year = {2026},
volume = {104},
number = {8},
pages = {891--899},
doi = {10.1159/000550347}
}
EUVIMED